Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and ...

A Phase 3 study in lichen simplex chronicus was initiated. The Company announced positive results from a Phase 3 trial of Libtayo, which demonstrated that adjuvant treatment with Libtayo was the ...

The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. The company is expected to report its Q1 earnings on Tuesday, Apr. 29 ...

The company believes that, based on the regulatory strategy ... The investigation will determine whether administering low doses of THIO prior to Libtayo can enhance and prolong the immune response in ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...